ELVN Earnings & Financial Statements
Enliven Therapeutics, Inc.
$40.98
+$0.35(+0.86%)
45
Overall
60
Value
36
Tech
39
Quality
Market Cap
$3.00B
Volume
1.00M
52W Range
$14.79 - $62.32
Target Price
$72.75
ELVN earnings and financial statements: Enliven Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ELVN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$51.44M |
| EBITDA | -$119.67M | -$103.37M | -$71.29M | -$37.45M | -$51.13M |
| Net income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$51.38M |
| EPS (diluted) | $-1.83 | $-1.89 | $-2.01 | $0.24 | $-9.48 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $476.17M | $325.76M | $271.87M | $83.30M | $93.65M |
| Total liabilities | $16.57M | $15.91M | $25.96M | $10.37M | $7.62M |
| Shareholders’ equity | $459.60M | $309.85M | $245.91M | $72.92M | $86.03M |
| Cash and equivalents | $98.90M | $124.12M | $100.14M | $75.54M | $48.31M |
| Long-term debt | - | - | - | - | $406.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | -$19.13M |
| Capital expenditure | $55.0K | -$44.0K | -$149.0K | -$612.0K | -$191.0K |
| Free cash flow | -$70.46M | -$73.24M | -$61.42M | -$32.69M | -$19.32M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELVN | $40.98 | +0.9% | 1.00M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enliven Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW